Search

Purpose: To compare the locoregional control achieved with whole breast irradiation (WBI) and accelerated partial breast irradiation (APBI) in women with ductal carcinoma in situ (DCIS). Methods: We used an institutional, IRB-approved database to retrospectively identify women with primary DCIS lesions less than 3 cm from 1995 to 2014, who underwent negative-margin breast conserving surgery (BCS) followed by either WBI or APBI. Cox-proportional hazard analysis was performed to estimate risks of in-breast tumor recurrence (IBTR) and regional nodal recurrence (RNR), adjusting for age of patient at diagnosis. Results: Three-hundred and eighty women were identified. Seventy-nine percent received WBI and 21% underwent APBI. Among women receiving WBI, 15.4% received a sequential lumpectomy cavity boost. APBI was delivered via high-dose-rate (HDR) brachytherapy technique, utilizing either a multi-catheter interstitial or single-entry intracavitary approach. The median follow-up time was 6 years for women who received WBI, and 8.9 years for women who received APBI. The actuarial 10-year IBTR rate was 9.0% for WBI and 8.75% for APBI (p = 0.94). The actuarial 10-year isolated regional nodal recurrence (RNR) rate was 0% for WBI and 2.5% for APBI. Among women who received WBI, the 10-year IBTR rate was 10.0% without lumpectomy cavity boost and 6.36% with boost (p = 0.40). Increasing age correlated with a lower risk of recurrence, regardless of treatment modality (p = 0.005). Conclusions: No differences in locoregional control was detected for women with DCIS measuring Citation Format: Katarina T Nguyen, David Francis, Thevaa Chandering, Kelli Pointer, Bethany Anderson. Clinical outcomes achieved with brachytherapy vs whole breast irradiation for ductal carcinoma in situ [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P6-16-05.

Few case studies have indicated that rituximab may be helpful in achieving clinical and serologic remission of dermatitis herpetiformis. We present a case of a 47-year-old man with celiac disease refractory to standard treatments who achieved clinical resolution of dermatitis herpetiformis with rituximab.